宣肺解痉方治疗支气管哮喘疗效及对血清TGF-β_(1)、MMP-9、VEGF的影响  

Efficacy of Xuanfei Jiejing Decoction in the treatment of bronchial asthma and its effect on serum TGF-β_(1),MMP-9 and VEGF

作　　者：任苓苓 张丽娟 王令敏 杨真卿 武蕾[2] 郭洁[2] 田雪娇 彭飞飞 REN Lingling;ZHANG Lijuan;WANG Lingmin;YANG Zhenqing;WU Lei;GUO Jie;TIAN Xuejiao;PENG Feifei(The First Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Shijiazhuang 050011, Hebei, China;Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050011, Hebei, China)

机构地区：[1]河北中医学院第一附属医院,河北石家庄050011 [2]河北省中医院,河北石家庄050011

出　　处：《现代中西医结合杂志》2022年第2期192-197,共6页Modern Journal of Integrated Traditional Chinese and Western Medicine

基　　金：河北省科技厅科研计划项目(192777130D);河北省中医药管理局科研计划项目(2020015,2020018,2020025,2021080)。

摘　　要：目的观察宣肺解痉方联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘慢性持续期临床疗效及对血清中转化生长因子-β_(1)(TGF-β_(1))、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)的影响。方法选择2019年10月—2020年11月河北省中医院诊治的支气管哮喘慢性持续期患者64例,随机分为治疗组和对照组,每组32例。对照组给予布地奈德福莫特罗粉吸入剂(160μg/4.5μg)吸入,每次1吸,每日2次;治疗组在对照组治疗的基础上给予宣肺解痉方加减口服,每日1剂连服30 d。观察2组治疗前后临床症状体征评分、哮喘控制测试(ACT)评分、肺功能指标[第1秒用力呼气容积占预计值百分比(FEV_(1)%)、第1秒用力呼气容积与用力肺活量比值(FEV_(1)/FVC)]、圣·乔治医院呼吸问题调查问卷(SGRQ)评分及血清中TGF-β_(1)、MMP-9、VEGF水平变化,比较2组临床疗效。结果治疗后2组ACT评分明显提高,临床症状体征评分、SGRQ评分明显降低,差异均有统计学意义(P均<0.05),且治疗组各评分改善情况均明显优于对照组(P均<0.05);治疗后2组FEV_(1)%、FEV_(1)/FVC均明显提高(P均<0.05),且治疗组均明显高于对照组(P均<0.05);治疗后2组血清中TGF-β_(1)、MMP-9、VEGF水平均明显降低(P均<0.05),且治疗组均明显低于对照组(P均<0.05);治疗组总有效率为90.6%(29/32),明显高于对照组的80.0%(24/32),差异有统计学意义(P<0.05)。结论宣肺解痉方联合布地奈德福莫特罗粉吸入剂可有效缓解支气管哮喘慢性持续期患者的临床症状,改善肺功能,降低血清炎症因子水平,改善气道重塑,提高患者生活质量。Objective It is to observe the clinical efficacy of Xuanfei Jiejing Decoction combined with budesonide formoterol powder inhalation in the treatment of chronic persistent bronchial asthma and its effect on serum transforming growth factor β_(1)(TGF-β_(1)),matrix metalloproteinase 9(MMP-9),vascular endothelial growth factor(VEGF).Methods A total of 64 patients with chronic persistent bronchial asthma who were diagnosed and treated in Hebei Provincial Hospital of Traditional Chinese Medicine from October 2019 to November 2020 were selected and randomly divided into a treatment group and a control group,with 32 cases in each group.The control group was given budesonide formoterol powder inhalation(160μg/4.5μg)by inhalation,1 inhalation each time,twice per day;the treatment group was given the modified Xuanfei Jiejing Decoction orally on the basis of the treatment of the control group,one dose per day for 30 days.The scores of clinical symptoms and signs,asthma control test(ACT)scores,and pulmonary function indexes[the percentage of forced expiratory volume in 1 second to predicted value(FEV1%),the ratio of forced expiratory volume in 1 second to forced vital capacity(FEV1/FVC)],St.George’s Hospital Respiratory Questionnaire(SGRQ)scores and serum levels of TGF-β_(1),MMP-9 and VEGF were observed before and after treatment in the two groups,the clinical efficacy of the two groups was compared.Results After treatment,the ACT scores were significantly improved,and the scores of clinical symptoms and signs and SGRQ scores were significantly decreased in the two groups,the differences were statistically significant(all P<0.05),the improvements of these scores in the treatment group were better than those in the control group(all P<0.05).After treatment,FEV_(1)%and FEV_(1)/FVC in the two groups were significantly increased(P<0.05),and the treatment group was significantly higher than the control group(P<0.05).After treatment,the serum levels of TGF-β_(1),MMP-9 and VEGF in the two groups were significantly decreased(

关 键 词：支气管哮喘 宣肺解痉方 气道重塑 转化生长因子-β_(1) 基质金属蛋白酶-9 血管内皮生长因子 

分 类 号：R562.25[医药卫生—呼吸系统]